Present and future challenges in therapeutic designing using computational approaches

Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection · 2022 · PMC9300749

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Although regulatory and phase III expenses for a repurposed drug may be similar to those for a new drug in the same indication, there may be significant savings in preclinical and phase I and II costs.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.